A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors

Ute Gawlick, David M Kranz, Victor D. Schepkin, Edward J Roy

Research output: Contribution to journalArticle

Abstract

T cell immunotherapy is a potential strategy for the treatment of brain tumors because it offers a high degree of specificity, the ability to extravasate into solid tumors, and the potential for eliciting a long-term protective immune response. Various approaches have been developed to overcome T cell immune tolerance to cancer, including the use of cytokines and bispecific antibodies. T cell stimulation with the proinflammatory cytokine IL-12 can elicit antitumor immunity. T cell activation can be increased using bispecific antibodies against activating molecules on the surface of T cells and a tumor antigen. We studied the effects of systemic IL-12 administration in combination with a conjugate of an anti-CD28 antibody and a ligand for the folate receptor. The high affinity folate receptor is expressed on endogenously arising choroid plexus tumors of SV11 mice, which are transgenic for large T antigen under the control of the SV40 promoter. SV11 mice are immunocompetent, yet immunologically tolerant to large T antigen expressed by choroid plexus tumors. MRI analysis showed that the administration of IL-12 and anti-CD28 Fab/folate significantly slowed tumor growth. Proliferating CD8+ T cells were found in choroid plexus tumors of treated animals. Treatment of animals with IL-12 + anti-CD28 Fab/folate prolonged survival compared to IL-12 alone. Cytokine treatment combined with tumor-targeted costimulation may be a useful adjunct treatment.

Original languageEnglish (US)
Pages (from-to)1137-1145
Number of pages9
JournalBioconjugate Chemistry
Volume15
Issue number5
DOIs
StatePublished - Sep 1 2004

Fingerprint

T-cells
Antibodies
Brain Neoplasms
Interleukin-12
Tumors
Brain
Choroid Plexus Neoplasms
Ligands
T-Lymphocytes
Folic Acid
Bispecific Antibodies
Neoplasms
Antigens
Viral Tumor Antigens
Cytokines
Animals
Immune Tolerance
Neoplasm Antigens
Therapeutics
Immunotherapy

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors. / Gawlick, Ute; Kranz, David M; Schepkin, Victor D.; Roy, Edward J.

In: Bioconjugate Chemistry, Vol. 15, No. 5, 01.09.2004, p. 1137-1145.

Research output: Contribution to journalArticle

@article{b455edbc17db4b3481ccf9c9e7cc4bb5,
title = "A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors",
abstract = "T cell immunotherapy is a potential strategy for the treatment of brain tumors because it offers a high degree of specificity, the ability to extravasate into solid tumors, and the potential for eliciting a long-term protective immune response. Various approaches have been developed to overcome T cell immune tolerance to cancer, including the use of cytokines and bispecific antibodies. T cell stimulation with the proinflammatory cytokine IL-12 can elicit antitumor immunity. T cell activation can be increased using bispecific antibodies against activating molecules on the surface of T cells and a tumor antigen. We studied the effects of systemic IL-12 administration in combination with a conjugate of an anti-CD28 antibody and a ligand for the folate receptor. The high affinity folate receptor is expressed on endogenously arising choroid plexus tumors of SV11 mice, which are transgenic for large T antigen under the control of the SV40 promoter. SV11 mice are immunocompetent, yet immunologically tolerant to large T antigen expressed by choroid plexus tumors. MRI analysis showed that the administration of IL-12 and anti-CD28 Fab/folate significantly slowed tumor growth. Proliferating CD8+ T cells were found in choroid plexus tumors of treated animals. Treatment of animals with IL-12 + anti-CD28 Fab/folate prolonged survival compared to IL-12 alone. Cytokine treatment combined with tumor-targeted costimulation may be a useful adjunct treatment.",
author = "Ute Gawlick and Kranz, {David M} and Schepkin, {Victor D.} and Roy, {Edward J}",
year = "2004",
month = "9",
day = "1",
doi = "10.1021/bc049911e",
language = "English (US)",
volume = "15",
pages = "1137--1145",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors

AU - Gawlick, Ute

AU - Kranz, David M

AU - Schepkin, Victor D.

AU - Roy, Edward J

PY - 2004/9/1

Y1 - 2004/9/1

N2 - T cell immunotherapy is a potential strategy for the treatment of brain tumors because it offers a high degree of specificity, the ability to extravasate into solid tumors, and the potential for eliciting a long-term protective immune response. Various approaches have been developed to overcome T cell immune tolerance to cancer, including the use of cytokines and bispecific antibodies. T cell stimulation with the proinflammatory cytokine IL-12 can elicit antitumor immunity. T cell activation can be increased using bispecific antibodies against activating molecules on the surface of T cells and a tumor antigen. We studied the effects of systemic IL-12 administration in combination with a conjugate of an anti-CD28 antibody and a ligand for the folate receptor. The high affinity folate receptor is expressed on endogenously arising choroid plexus tumors of SV11 mice, which are transgenic for large T antigen under the control of the SV40 promoter. SV11 mice are immunocompetent, yet immunologically tolerant to large T antigen expressed by choroid plexus tumors. MRI analysis showed that the administration of IL-12 and anti-CD28 Fab/folate significantly slowed tumor growth. Proliferating CD8+ T cells were found in choroid plexus tumors of treated animals. Treatment of animals with IL-12 + anti-CD28 Fab/folate prolonged survival compared to IL-12 alone. Cytokine treatment combined with tumor-targeted costimulation may be a useful adjunct treatment.

AB - T cell immunotherapy is a potential strategy for the treatment of brain tumors because it offers a high degree of specificity, the ability to extravasate into solid tumors, and the potential for eliciting a long-term protective immune response. Various approaches have been developed to overcome T cell immune tolerance to cancer, including the use of cytokines and bispecific antibodies. T cell stimulation with the proinflammatory cytokine IL-12 can elicit antitumor immunity. T cell activation can be increased using bispecific antibodies against activating molecules on the surface of T cells and a tumor antigen. We studied the effects of systemic IL-12 administration in combination with a conjugate of an anti-CD28 antibody and a ligand for the folate receptor. The high affinity folate receptor is expressed on endogenously arising choroid plexus tumors of SV11 mice, which are transgenic for large T antigen under the control of the SV40 promoter. SV11 mice are immunocompetent, yet immunologically tolerant to large T antigen expressed by choroid plexus tumors. MRI analysis showed that the administration of IL-12 and anti-CD28 Fab/folate significantly slowed tumor growth. Proliferating CD8+ T cells were found in choroid plexus tumors of treated animals. Treatment of animals with IL-12 + anti-CD28 Fab/folate prolonged survival compared to IL-12 alone. Cytokine treatment combined with tumor-targeted costimulation may be a useful adjunct treatment.

UR - http://www.scopus.com/inward/record.url?scp=4644258655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644258655&partnerID=8YFLogxK

U2 - 10.1021/bc049911e

DO - 10.1021/bc049911e

M3 - Article

C2 - 15366970

AN - SCOPUS:4644258655

VL - 15

SP - 1137

EP - 1145

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 5

ER -